Balaxi Pharmaceuticals Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 598.33 million compared to INR 806.82 million a year ago. Revenue was INR 580.47 million compared to INR 80,461.3 million a year ago. Net income was INR 109.34 million compared to INR 81 million a year ago. Basic earnings per share from continuing operations was INR 2.082 compared to INR 1.602 a year ago. Diluted earnings per share from continuing operations was INR 2.076 compared to INR 1.572 a year ago.
For the full year, sales was INR 2,412.94 million compared to INR 3,364.33 million a year ago. Revenue was INR 2,386.48 million compared to INR 3,390.7 million a year ago. Net loss was INR 23.87 million compared to net income of INR 459.63 million a year ago. Basic loss per share from continuing operations was INR 0.464 compared to basic earnings per share from continuing operations of INR 9.162 a year ago.